Semaglutide and Terzepatide are the generic forms of the popular weight loss medication Ozembic/Wegovy and Mounjaro.  They are FDA approved for weight loss and studies show in non-diabetics who are overweight with one comorbidity, this medication with lifestyle changes led to a 14.9% mean weight loss. More than 50% of trial participants lost 15% of their body weight, and between 33% to 40% lost 20% of their body weight. 

In a recent trial, Patients that are overweight with established cardiovascular disease without diabetes, Semaglutide was associated with a 20% reduction in major adverse cardiac events!